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The surveillance of pneumococcal antibiotic resistance and serotype distribution is hampered by the relatively
low numbers of invasive pneumococcal infections. In Switzerland, a nationwide sentinel surveillance network
was used to assess antibiotic resistance and serotype distribution among 1179 pneumococcal isolates cultured
from 2769 nasopharyngeal swabs obtained from outpatients with acute otitis media or pneumonia during 1998
and 1999. The proportion of penicillin-susceptible pneumococcal isolates overall (87%) and among infants !2
years old (81%) was comparable to that of invasive isolates (90% and 81%, respectively). The high number of
nasopharyngeal isolates allowed for the detection of a rapid increase in the number of penicillin-nonsusceptible
pneumococcal (PNSP) strains in the West region of Switzerland, partly because of an epidemic caused by the
19F clone of Streptococcus pneumoniae. Clustering of risk factors for the carriage of PNSP isolates further explained
the geographic variation in resistance rates. The nationwide sentinel surveillance of nasopharyngealpneumococcus
proved to be valuable for the monitoring of antibiotic resistance, risk factors for carriage of PNSP isolates, and
serotype distribution and for the detection of the emergence of a new epidemic clone.
Streptococcus pneumoniae remains one of the most im-
portant human pathogens that causes severe invasive
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infections (e.g., meningitis, sepsis, and pneumonia) and
frequent upper respiratory tract infections (e.g., acute
otitis media [AOM]). Of additional concern is the in-
creasing frequency and rapid spread of drug-resistant
pneumococcal strains worldwide. Surveillance of an-
tibiotic resistance prevalence and identification of risk
factors for the emergence and spread of resistant strains
at local, national, and international levels are primary
strategies in combating antibiotic resistance [1–3]. In
addition, the introduction of the new conjugated pneu-
mococcal polysaccharide vaccines stresses the need for
intensified surveillance of S. pneumoniae for timely rec-
ognition of serotype redistribution and the emergence
of new serotypes [4, 5].
Surveillance of S. pneumoniae is demanding. It must
include invasive and noninvasive pneumococcal infec-
tions, antibiotic resistance prevalence, and capsular
serotype distribution, as well as relevant sociodemo
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graphic and clinical data. However, pneumococcal epidemiology
poses several challenges to valid and comprehensive surveillance.
First, documented invasive pneumococcal infections are relatively
rare, which leads to statistical problems, especially after risk-
group analysis. Second, some S. pneumoniae serotypes exhibit a
distinctive epidemiology, with regard to their potential to cause
invasive disease, their predominance in certain age groups, and
their geographic distribution. Adequate sample sizes are required
for data stratification and detection of such disease-specific ser-
ogroup differences [6]. Third, the observed frequency of invasive
infections and serotype distribution may be biased by the practice
of taking blood cultures [7]. Fourth, valid diagnostic tests for
the identification of noninvasive pneumococcal infections are
not available, such as tests for pneumonia, or are not routinely
used, such as tests for tympanocentesis. Finally, serotyping is
not performed routinely in most clinical microbiology labo-
ratories, which requires setting up a reference laboratory. In
1996, the Centers for Disease Control and Prevention (CDC)
recommended that nasopharyngeal isolates be used for the sur-
veillance of the pneumococcal epidemiology, since they can be
obtained in higher numbers than invasive isolates [1].
In addition, epidemiological data on nasopharyngeal pneu-
mococci harbor valuable information. At the population level,
the prevalence of antibiotic resistance among nasopharyngeal
pneumococci has been found to be a valid estimate for the strains
involved in AOM [8]. In patients with AOM, a culture result
from a nasopharyngeal swab that is negative for pneumococcus
has a high negative predictive value (i.e., the likelihood of S.
pneumoniae being present in the middle-ear fluid is very low
[9]). In addition, if pneumococcus can be cultured from such a
swab but shows no antibiotic resistance traits, the likelihood of
a resistant pneumococcus in the middle-ear fluid is small [9].
In the present study, an established nationwide sentinel sur-
veillance network was used to evaluate the antibiotic resistance
prevalence and serotype distribution in nasopharyngeal samples
from outpatients with AOM or pneumonia in Switzerland dur-
ing 1998 and 1999. The Swiss Federal Office of Health (SFOH)
simultaneously conducted another nationwide surveillance
study on invasive pneumococcal infections [10], which allowed
for the comparison of the results obtained from nasopharyngeal
and invasive isolates.
METHODS
Swiss Sentinel Surveillance Network. The Swiss Sentinel
Surveillance Network was established in 1986 (http://www
.admin.ch/bag/sentinella/). It consists of a selected sample of
practitioners who represent the country geographically and
demographically. The total number of participants per sub-
specialty in the network is defined as a percentage of all Swiss
practitioners in the corresponding specialty (i.e., ∼3% of gen-
eral practitioners, 10% of pediatricians, etc.), according to the
statistics of the Swiss Medical Association (available at http://
www.fmh.ch/). For the selection process, the country is divided
into a grid of 240 cells, considering the distribution of all phy-
sicians (by subspecialty), the 26 political states (cantons), and
urban versus rural regions. The number of participating phy-
sicians in each cell is then determined as a proportion of all
physicians in that cell. Recruitment of participants is done by
annual open advertisement and direct contact through regional
representatives. Participation is voluntary. A recent analysis
showed that participating physicians are representative of the
whole collective of Swiss practitioners [11]. In 1999, the na-
tionwide network comprised 231 regularly reporting participants
(130 general practitioners, 66 internists, and 35 pediatricians),
accounting for ∼3.5% of Swiss practitioners. Anonymous, pa-
tient-related data for an average of 5 projects/year, such as in-
fluenza, measles, mumps, rubella, pertussis, and asthma, are re-
ported to the SFOH on a weekly basis.
Collection of isolates and data. Between 1 January 1998
and 31 December 1999, participating practitioners submitted
nasopharyngeal swabs of outpatients !17 years old or 164 years
old who presented with AOM or pneumonia, according to CDC
definitions (available at http://www.cdc.gov/epo/dphsi/casedef/
index.htm). Only results for the pediatric population !17 years
old are presented here. Swabs were obtained with twisted wire
rayon tipped applicators (Copan Ventury Transystem; Copan).
All samples were sent to the Institute for Infectious Diseases
(University of Bern) for microbiological analysis. Patients were
enrolled repeatedly for each new episode of AOM or pneu-
monia. With each sample, practitioners submitted a standard-
ized questionnaire listing the patient’s age, sex, place of resi-
dence, diagnosis, antibiotic treatment during the previous 8
weeks (yes or no), the number of AOM episodes during the
last 12 months, and current day care attendance (yes or no).
Microbiological methods. Swabs were plated onto Colum-
bia agar with 5% sheep blood and incubated at 35C in a 5%
CO2-enriched atmosphere for 48 h. S. pneumoniae was iden-
tified by colony morphology and inhibition with optochin. One
morphotype per plate was subcultured and frozen at 80C
(Protect; Technical Service).
All isolates were tested against oxacillin (1 mg disc), eryth-
romycin, and cotrimoxazol by the disc diffusion method [12].
For isolates with reduced susceptibility against any of these 3
antibiotics, MICs were determined against penicillin, erythro-
mycin, cotrimoxazol, azithromycin, cefaclor, cefprozil, cef-
triaxon, cefuroxime, chloramphenicol, ofloxacin, tetracyclin,
and vancomycin, by use of the E-test method (AB Biodisk),
according to National Committee for Clinical Laboratory Stan-
dards (NCCLS) guidelines [12]. MICs for gatifloxacin and ri-
fampicin were determined using the E-test method for peni-
cillin-nonsusceptible pneumococcal (PNSP) isolates (defined as
Table 1. Characteristics of 1179 pediatric pneumococcal isolates from the Swiss
Sentinel Study on pneumococcus, 1998–1999.
Characteristic PSP PNSP P
Total 1022 (86.6) 157 (13.4)
Diagnosis
AOM 966 (94.5) 145 (92.4)
Pneumonia 45 (4.4) 11 (7.0)
Age, years !.001
0–1 291 (28.5) 69 (43.9)
2–4 373 (36.5) 48 (30.6)
5–16 358 (35.0) 40 (25.5)
Female 515/1022 (50.4) 73/157 (46.5)
Antibiotic therapy in the last 8 weeksa 160/894 (17.8) 40/142 (28.2) .005
Currently attending day carea 135/858 (15.7) 33/142 (23.2) .03
11 episode of AOM in the last 12 monthsa 157/857 (18.3) 38/141 (26.9) .003
West region of Switzerlanda 549/1016 (54.0) 117/157 (74.5) !.001
Drug to which isolate is susceptibleb
Erythromycin 935 (91.5) 87 (55.4) !.001
Cotrimoxazol 885 (86.5) 92 (58.5) !.001
Gatifloxacin 100 (100) 153 (100)
Rifampicin 100 (100) 153 (100)
Serotype or serogroupc
4 5 (1.6) 0 (0)
6B 32 (10.5) 14 (9)
9V 11 (3.6) 9 (5.8)
14 30 (9.9) 20 (12.9)
18C 9 (3.0) 0 (0)
19F 55 (18.1) 40 (25.8) .05
23F 34 (11.2) 11 (7.1)
Total 304 (100) 155 (100)
Future vaccine types (1, 3, 5, or 7F) 19 (6.3) 2 (1.3)
6A 27 (8.9) 6 (3.9) .04
19A 10 (3.3) 13 (8.4) .01
Other types 72 (23.6) 43 (25.8)
7-V PnCCd 176 (57.9) 94 (59.9)
9-V PnCCd 180 (59.2) 95 (60.5)
11-V PnCCd 195 (64.1) 96 (61.1)
NOTE. Data are no. (%) of isolates, except where noted. Of the 1179 pneumococcal isolates, 288
(24.4%) were from patients with repeated new episodes of acute otitis media (AOM) or pneumonia; of
these, 18% had 2 swabs taken (2 disease episodes). PNSP, penicillin-nonsusceptible pneumococci; PSP,
penicillin-susceptible pneumococci.
a Data are no./total no. (%) of isolates. Logistic regression analysis for risk factors of carriage of PNSP
isolates yielded the following crude odds ratios (cORs), adjusted odds ratios (aORs), and 95% confidence
intervals (CIs). Age: 0–1 years old, reference; 2–4 years old, and (95% CI,cORp 0.54 aORp 0.56
0.37–0.85); and 5–16 years old, and (95% CI 0.29–0.71); antibiotic therapy:cORp 0.47 aORp 0.45
and (95% CI, 1.10–2.45); 11 episode of AOM: (95% CI, 1.09–2.48);cORp 1.79 aORp 1.65 cORp 1.64
currently attending day care: (95% CI, 1.05–2.49); West region of Switzerland:cORp 1.62 cORp
(95% CI, 1.70–3.64). Only age and antibiotic therapy remained independent risk factors after ad-2.48
justment and were included in the final model.
b Susceptibilities to gatifloxacin and rifampicin were tested in a random sample of 100 PSP isolates
and in 153 of a total of 157 PNSP isolates.
c Serogroup or serotype was determined for 155 of 157 PNSP isolates.
d 7-V PnCC, expected coverage for the conjugated 7-valent (serotypes 4, 6B, 9V, 14, 18C, 19F, and
23F) pneumococcal vaccine; 9-V PnCC, expected coverage for the 9-valent (7-V PnCC plus serotypes 1
and 5) pneumococcal vaccine; and 11-V PnCC, expected coverage for the 11-valent (9-V PnCC plus
serotypes 3 and 7F) pneumococcal vaccine.
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Table 2. Geographic distribution of pneumococcal susceptibility and risk factors for carriage of penicillin-
nonsusceptible pneumococcal isolates among children with respiratory infections, Swiss Sentinel Study,
1998–1999.
Drug, year, age group Westa Easta OR (95% CI) P
Penicillin
1998
!2 years 93 (80.2) 48 (88.9) .2
!17 years 317 (85.2) 220 (91.6) .01
1999
!2 years 78 (70.9) 71 (89.9) .003
!17 years 232 (78.9) 247 (92.5) !.001
Erythromycin
1998
!2 years 96 (82.8) 49 (90.7) .15
!17 years 316 (84.9) 215 (89.5) .09
1999
!2 years 84 (76.4) 70 (88.6) .02
!17 years 239 (81.3) 248 (92.8) !.001
Cotrimoxazol
1998
!2 years 92 (79.3) 46 (85.2) .48
!17 years 303 (81.4) 209 (87.1) .06
1999
!2 years 68 (61.8) 64 (81.0) .007
!17 years 208 (70.7) 224 (83.9) !.001
Demographic characteristicsb
Antibiotic therapy in previous 8 weeks 139/571 (24.3) 60/459 (13.1) 2.00 (1.40–2.77) !.001
11 episode of AOM in the last 12 months 146/554 (26.4) 49/438 (11.9) 2.71 (1.90–3.87) !.001
Currently attending day care 113/547 (20.7) 53/447 (11.9) 1.96 (1.36–2.85) !.001
NOTE. Data are no. (%) of isolates, except where noted. AOM, acute otitis media; CI, confidence interval; OR, odds
ratio (adjusted for age and study year [1998 or 1999]).
a Information on place of residency was missing for 6 patients.
b Data are no./total (%) of isolates.
MIC 10.06 mg/L) and a random sample of 100 penicillin-
susceptible pneumococcal (PSP) isolates. Interpretation of
MICs was done according to NCCLS guidelines, with the ex-
ception of gatifloxacin (sensitive, 1 mg/L; resistant, 4 mg/
L) [13].
Capsular typing was done on all isolates with reduced sus-
ceptibility to penicillin, erythromycin, or cotrimoxazol (np
). In addition, a random sample of 95 PSP isolates was364
chosen for serotyping using a random number table. The Quel-
lung reaction was performed using antiserum from the Statens
Serum Institute (Copenhagen).
Pulsed-field gel electrophoresis (PFGE) typing was done on
all isolates of serogroup 19, as described elsewhere [14], by use
of SmaI for restriction of chromosomal DNA. Isolates were
grouped into the same clone if they shared the same capsule
type and if their pattern differed by 3 bands [15]. Represen-
tative strains of 19F clones were further analyzed by multilocus
sequence typing (MLST), as described elsewhere [16].
Statistical analysis. Risk factors for pneumococcal carriage
with PNSP isolates were evaluated by univariate and multivariate
analysis. Variables were coded as described above. Two geograph-
ic regions were defined: the East region, which represents large-
ly the German-speaking part of Switzerland, together with the
much smaller Italian- and Roman-speaking regions, and the West
region, which represents largely the French-speaking cantons. It
is well known that the Swiss German and the French population
differ according to several sociodemographic and socioeconomic
factors, including behaviors and political orientation.
Risk factors identified by univariate statistics were entered
into a logistic regression model using StatView (version 5.0;
SAS Institute). The final model contained the largest number
of variables, with . Proportions were compared with theP .05
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Table 3. Serotype distribution among 304 penicillin-susceptible
pneumococcal (PSP) and 155 penicillin-nonsusceptible pneu-
mococcal (PNSP) nasopharyngeal isolates, by geographic region
and age, Swiss Sentinel Study, 1998–1999.
Serotype
Region Age !2 years
East West PSP PNSP
1 1 (0.6) 4 (1.4) 0 (0) 0 (0)
3 9 (5.3) 6 (2.1) 4 (4.1) 0 (0)
4 4 (2.4) 1 (0.3) 4 (4.1) 0 (0)
5 0 (0) 0 (0) 0 (0) 0 (0)
6Ba 11 (6.5) 35 (12.1) 12 (12.4) 7 (10.1)
7F 1 (0.6) 0 (0) 0 (0) 0 (0)
9V 9 (5.3) 11 (3.8) 3 (3.1) 5 (7.2)
14 18 (10.7) 32 (11) 12 (12.4) 6 (8.7)
18C 6 (3.6) 3 (1) 3 (3.1) 0 (0)
19Fa 27 (16.0) 68 (23.4) 22 (22.7) 21 (30.4)
19F clonea 8 (4.7) 38 (13.1) 7 (7.2) 8 (11.6)
23Fa 7 (4.1) 38 (13.1) 12 (12.4) 6 (8.7)
7-V PnCb 82 (48.5) 188 (64.8) 68 (70.1) 45 (65.2)
9-V PnCb 83 (49.1) 192 (66.2) 68 (70.1) 45 (65.2)
11-V PnCb 93 (55.0) 198 (68.3) 72 (74.2) 45 (65.2)
6A 0 (0) 1 (0.3) 4 (4.1) 4 (5.8)
19A 6 (3.6) 17 (5.9) 3 (3.1) 8 (11.6)
Other 70 (41.4) 74 (25.5) 18 (18.5) 12 (17.3)
Total 169 (100) 290 (100) 97 (100) 69 (100)
NOTE. Data are no. (%) of isolates.
a Serotypes 6B ( ), 19F ( ), 19F clone ( ), and 23FPp .05 Pp .05 Pp .006
( ) occurred significantly more frequently in the West region. “19FPp .003
clone” refers to the most frequent serotype 19F clone observed in this study.
b Expected coverage for the conjugated 7-valent (7-V PnC: serotypes 4, 6B,
9V, 14, 18C, 19F and 23F) pneumococcal vaccine, the conjugated 9-valent
vaccine (7-valent plus serotypes 1 and 5), and the conjugated 11-valent vaccine
(9-valent plus serotypes 3 and 7F).
x2 or Fisher’s exact test, as appropriate. Differences between
means were assessed by the Student’s t test. A cutoff of 2-tailed
was used for all statistical analyses.P .05
RESULTS
Samples analyzed. In total, 2769 nasopharyngeal swabs were
cultured from children !17 years old, and S. pneumoniae was
isolated from 1179 (43%) of these samples. The age-specific car-
riage rates were as follows: 48.3% for the 0–1-year-old group,
48.1% for the 2–4-year-old group, and 38.7% for the 5–16-year-
old group. These carriage rates compared well with those found
in other studies [17, 18]. Of the 1179 pneumococcal isolates, 288
(24%) were from patients who had repeated swabs taken; 210
(73%) patients had 2 swabs taken. Isolates from the same patients
were sampled at least 2 months apart. The isolates were evenly
distributed between the study years and the 2 defined geographic
regions (data not shown). Study patients predominantly had
AOM (93%). Nineteen percent of study patients had received
antibiotics during the preceding 8 weeks, ∼20% had 11 episode
of AOM during the last 12 months, and ∼17% were attending
day care at the time of the outpatient visit.
Antibiotic susceptibility rates. Overall susceptibility of
pneumococcal isolates was 87% for penicillin, 87% for eryth-
romycin, and 81% for cotrimoxazol. High resistance to peni-
cillin (MIC 11 mg/L) was rare (29/1179 isolates [2.5%]), and
the highest observed MIC against penicillin was 12 mg/L. MICs
for erythromycin showed a bimodal distribution (data not
shown); most PNSP isolates (111/142 [78.1%]) had MICs 132
mg/L, which is compatible with a macrolide, lincosamide, and
streptogramin B resistance phenotype [19]. Multidrug resis-
tance was frequent among PNSP isolates (table 1). Half the
PNSP isolates were resistant to macrolides and cotrimoxazol.
Susceptibility rates among PNSP isolates to other antibiotics
were as follows: cefaclor, 45.7%; cefprozile, 73.2%; cefuroxime,
75.1%; ceftriaxone, 84.3% (no high level resistance); chloram-
phenicol, 85.6%; ofloxacin, 71.0%; tetracyline, 51.0%; and van-
comycin, 100%. The proportion of PNSP isolates and cotri-
moxazol-resistant strains increased rapidly between 1998 and
1999, primarily in the youngest age group residing in the West
region of Switzerland; in 1999, it reached 29% for penicillin
and 38% for cotrimoxazol (table 2).
Risk factors for carriage of PNSP isolates. Carriage of
PNSP isolates was significantly associated with age !2 years,
antibiotic therapy during the last 8 weeks, 11 episode of AOM
during the past 12 months, and current day care attendance
(table 1). In the logistic regression model, only age and recent
antibiotic therapy remained independent risk factors (table 1).
Resistance rates also were considerably higher in the West re-
gion of Switzerland, especially among children !2 years old
(table 1). This result could be explained by a significantly higher
prevalence of the risk factors for carriage of PNSP isolates in
the West region (table 2). Children residing in the West region
were twice as likely to have received antibiotic therapy, had a
2–3-fold higher probability of recurrent AOM, and were 20%
more likely to attend day care than children in the East region.
Serogroup distribution. Serogroup 19 and serotype 19F
were the most frequent serogroups observed (table 1). Serotypes
19F and 19A were significantly associated with PNSP isolates
(table 1) and residence in the West region (table 3). In addition,
serogroup 19 occurred most frequently among children !2
years old (table 3). Besides serotype 19F, the most prevalent
serotypes among PSP and PNSP isolates were, in decreasing
order of frequency, 23F, 6B, and 14 (table 3). None of these
other serotypes showed a similar association with PNSP. How-
ever, serotypes 6B and 23F also were more prevalent in the
West than in the East region (table 3). The expected coverage
for the new 7-valent conjugated pneumococcal vaccine was, on
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Figure 1. Differential dynamics of spread of the most prevalent observed serotype 19F clone between 1998 and 1999 in the East and West regions
of Switzerland. The surveillance period was stratified into 3 different time intervals, as indicated on the Z-axis. The percentage prevalence of serotype
19F clone is given regardless of susceptibility to penicillin (“West all” and “East all”), for penicillin-susceptible pneumococcal (PSP) isolates, and for
penicillin-nonsusceptible pneumococcal (PNSP) isolates. There were 6 serotype 19F clone isolates in January 1998 to August 1998 , 31 serotype 19F
clone isolates in September 1998 to April 1999, and 9 serotype 19F clone isolates in May 1999 to December 1999. The difference between East and
West for the proportions of all serotype 19F clone isolates was statistically significant for the time intervals September 1998 to April 1999 (Pp
, x2 test) and May 1999 to December 1999 ( , x2 test)..001 Pp .04
average, 60% (table 1). However, the expected coverage is∼70%
for children !2 years old and would be considerably higher in
the West than in the East region (table 3).
Molecular typing of 19F strains. PFGE revealed 4 clones
of serotype 19F of 46, 14, 4, and 2 isolates and 29 sporadic
strains. The largest clone comprised 21 PSP and 25 PNSP iso-
lates. MIC50 and MIC90 values to penicillin for PNSP isolates
were relatively low (0.094 mg/L). MLST revealed the following
allelic combination: aroE type 7, gdh type 14, gki type 4, spi
type 1, recP type 12, xpt type 1, and ddl type 14. According
to the MLST database (available at http://www.mlst.net/), this
clone did not correspond to any of the known, multidrug-
resistant clones [20]. Overall carriage of serotype 19F and car-
riage of the most frequently observed 19F clone were not more
associated with prior antibiotic therapy, recurrent AOM, and
day care attendance than other serotypes observed in this sur-
veillance study (data not shown).
Epidemic spread of serotype 19F clone. The relative pro-
portions of serotype 19F isolates increased between 1998 and
1999 from 10.8% (13/120) to 22.8% (42/184) among PSP iso-
lates ( , x2 test) and from 20.5% (15/73) to 30.5% (25/Pp .01
82) among PNSP isolates ( , x2 test). This change wasPp .10
largely due to the spread of the largest 19F clone described
above. After subtracting the number of isolates belonging to
the most frequent serotype 19F clone from the total number
of 19F isolates, the proportions of 19F strains in 1998 (8.8%)
and 1999 (12.0%) were not significantly different. Carriage of
the serotype 19F clone was associated with residence in the
West region (table 3). In addition, the rapid increase in PNSP
isolates in the West region in 1999 was due, at least in part, to
this clone. Of interest, PSP isolates of this serotype 19F clone
increased first in the West region and then spread to the East
region; the increase of PNSP isolates among this 19F clone was,
however, almost limited to the West region (figure 1).
DISCUSSION
The present study made use of an established sentinel network
of practitioners to assess the value of randomly collected na-
sopharyngeal swabs for nationwide pneumococcal surveillance.
A concurrent, nationwide, laboratory-based study of invasive
S. pneumoniae isolates allowed us to compare the 2 different
surveillance strategies [10].
In January 1998, invasive S. pneumoniae infections (defined
as the culture of pneumococcus from a sterile body site) became
a reportable disease in Switzerland. At the same time, a 2-year
pilot study was started on the collection of invasive S. pneu-
moniae isolates from clinical microbiology laboratories in a
reference laboratory. Over a period of 18 months (April 1998
to September 1999), 925 isolates were received by the reference
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center from 61 laboratories (of 77 contacted laboratories) and
were tested for antibiotic susceptibility and capsular serotype
[10]. The proportion of isolates from children !17 years old
was 14.9% (138 isolates).
Overall penicillin susceptibility rates for children !17 years
old were similar for nasopharyngeal (87%) and invasive isolates
(90%) [10]. In addition, children !2 years old had the lowest
susceptibility rates, with 81% in both studies. However, only
the ∼6-fold higher number of isolates obtained in the Sentinel
Study for children !2 years old (359 vs. 63 isolates) allowed
for a detailed analysis of resistance data. For example, only the
Sentinel data revealed the rapid increase of resistance rates be-
tween 1998 and 1999 in infants residing in the West region of
Switzerland. Resistance rates in nasopharyngeal and invasive
strains did not agree as well in a recent Canadian study as in
the data presented here; however, in the Canadian study, isolates
from children attending day care were compared with invasive
strains from the whole population, which may account for the
slightly higher resistance rates in the former [21].
The serotype distribution was similar between the nasopha-
ryngeal and invasive pneumococcal isolates with regard to the
most prevalent types, but the exact rank order differed. This
was equally the case for the overall serotype distribution among
children !17 years old and the distribution of serotypes among
the age group !2 years old. Serotype 19F was the most prevalent
type in nasopharyngeal isolates, whereas serotypes 14 and 1
predominated among invasive strains. The relatively high pro-
portion of serotype 19F in the Sentinel study is likely to be the
result of the epidemic spread of a new serotype 19F clone not
yet seen in the invasive isolates. It may be that the rapid epi-
demic spread of a serotype clone is reflected in invasive isolates
only after a certain lag time and that nasopharyngeal isolates
are a more-sensitive indicator for emerging clones. The relative
predominance of serotype 1 among invasive strains is char-
acteristic of European countries [22].
This Sentinel study also allowed us to identify previously
described risk factors for carriage of PNSP isolates (i.e., young
age, recurrent AOM, previous antibiotic treatment, and day
care attendance) [17, 23, 24]. The ∼2-fold higher prevalence
of some of the identified risk factors for PNSP isolate carriage
in the West region of Switzerland is likely to play an important
role for the higher resistance prevalence observed in this region.
No data on the specific antibiotics prescribed were obtained in
this study. Therefore, there are no data to explain the rapidly
increasing resistance to cotrimoxazole in the West region; how-
ever, use of this drug for prophylaxis against recurrent AOM
is a common practice in the West region of Switzerland.
The Sentinel Surveillance Network detected a new epidemic
serotype 19F clone. By use of MLST, this clone was not identical
or closely related to any of the described major multidrug-
resistant clones of S. pneumoniae [20]. According to the MLST
database, 2 strains have been recorded so far, both in Spanish
patients with meningitis in 1997. Recently, this clone also was
observed among clones isolated in day care centers in Portugal
[25]. The reason for the rapid epidemic spread of this 19F
clone in Switzerland remains unexplained. It is intriguing that
the clone comprises PSP and PNSP isolates and that only PSP
strains spread to the East region. We are currently analyzing
the characteristics of this clone and the question of whether
PNSP strains arise constantly de novo from PSP strains or are
predominantly transmitted.
Surveillance of nasopharyngeal isolates allows for the analysis
of large numbers of isolates, which is an advantage over invasive
isolates. However, even with the sentinel approach, the number
of available nasopharyngeal isolates in a nationwide surveillance
may be unnecessarily high for statistical precision and too abun-
dant for logistical reasons. The present study was, therefore, re-
stricted to children. This action was also motivated by the fact
that this patient group may have the greatest immediate benefit
from the obtained results at both the individual and population
levels for the choice of empiric therapy for AOM and pneumonia
[8, 9]. Whether the observed data also can be extrapolated to
children without AOM or pneumonia and the age groups not
covered by this study would have to be investigated by use of
other sampling algorithms. However, a recent study did not find
vast differences for resistance rates and serotype distributions
between nasopharyngeal pneumococci isolated from healthy in-
fants and infants with respiratory disease [18].
Therefore, nationwide sentinel surveillance of nasopharyn-
geal pneumococcus provided valuable data on antibiotic resis-
tance prevalence, risk factors for carriage of PNSP strains, and
serotype distribution. It allowed us to detect the epidemic emer-
gence of a new 19F clone associated with the spread of antibio-
tic resistance. These features will be of importance for pneu-
mococcal surveillance in the era of the new conjugate poly-
saccharide vaccines. In particular, they will allow for docu-
mentation of serotype replacement after the introduction of
widespread vaccination.
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